Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Other EventsItem 8.01 Other Events.
On January24, 2018, Trovagene,Inc. issued a press release announcing the initiation of its Phase 2 clinical trial, evaluating the combination of PCM-075 and abiraterone acetate (Zytiga® – Johnson& Johnson), in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC). A copy of the press release is furnished as Exhibit99.1 to this Form8-K.
Item 9.01. Financial Statements and Exhibits
(d)Exhibits.
|
99.1 |
Press Release of Trovagene,Inc. dated January24, 2018 |
Trovagene, Inc. ExhibitEX-99.1 2 a18-3716_1ex99d1.htm EX-99.1 Exhibit 99.1 Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) PCM-075,…To view the full exhibit click here
About Trovagene,Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
